PLA2R1 Antibody

中文名稱：

PLA2R1兔多克隆抗體
貨號：

CSB-PA623780LA01HU
規(guī)格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human kidney tissue using CSB-PA623780LA01HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) PLA2R1 Polyclonal antibody
Uniprot No.：

Q13018
基因名：

PLA2R1
別名：

180 kDa secretory phospholipase A2 receptor antibody; C-type lectin domain family 13 member C antibody; CLEC13C antibody; M type receptor antibody; M-type receptor antibody; Phospholipase A2 receptor 1 antibody; PLA2 R antibody; PLA2-R antibody; PLA2G1R antibody; PLA2IR antibody; PLA2R antibody; PLA2R_HUMAN antibody; PLA2R1 antibody; Soluble PLA2-R antibody; Soluble PLA2R antibody; Soluble secretory phospholipase A2 receptor antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Secretory phospholipase A2 receptor protein (395-530AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，PLA2R1 Antibody (CSB-PA623780LA01HU)，的標記方式是Non-conjugated。對于PLA2R1 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA623780LB01HU	PLA2R1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA623780LC01HU	PLA2R1 Antibody, FITC conjugated
Biotin	CSB-PA623780LD01HU	PLA2R1 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Receptor for secretory phospholipase A2 (sPLA2). Acts as a receptor for phospholipase sPLA2-IB/PLA2G1B but not sPLA2-IIA/PLA2G2A. Also able to bind to snake PA2-like toxins. Although its precise function remains unclear, binding of sPLA2 to its receptor participates in both positive and negative regulation of sPLA2 functions as well as clearance of sPLA2. Binding of sPLA2-IB/PLA2G1B induces various effects depending on the cell type, such as activation of the mitogen-activated protein kinase (MAPK) cascade to induce cell proliferation, the production of lipid mediators, selective release of arachidonic acid in bone marrow-derived mast cells. In neutrophils, binding of sPLA2-IB/PLA2G1B can activate p38 MAPK to stimulate elastase release and cell adhesion. May be involved in responses in proinflammatory cytokine productions during endotoxic shock. Also has endocytic properties and rapidly internalizes sPLA2 ligands, which is particularly important for the clearance of extracellular sPLA2s to protect their potent enzymatic activities. The soluble secretory phospholipase A2 receptor form is circulating and acts as a negative regulator of sPLA2 functions by blocking the biological functions of sPLA2-IB/PLA2G1B. In podocytes, binding of sPLA2-IB/PLA2G1B can regulate podocyte survival and glomerular homeostasis.
基因功能參考文獻：
1. Compared with non-PLA2R-associated IMN patients in our cohort, PLA2R-associated IMN patients presented with more severe proteinuria and lower remission rates after treatment, with no distinct histological differences. PMID: 30032157
2. Suggest strong genetic association between nonsynonymous SNP rs35771982 (p.His300Asp) within PLA2R1 and idiopathic membranous nephropathy. PMID: 28849274
3. We propose a revised clinical workup flow for patients with MN that recommends assessment of kidney biopsy for PLA2R1 and THSD7A antigen expression, screening for circulating anti-podocytes antibodies, and assessment for secondary causes, especially cancer, in patients with THSD7A antibodies PMID: 29511687
4. Five SNPs around the PLA2R1 gene were significantly associated with idiopathic membranous nephropathy. PMID: 27934873
5. Several risk alleles related to the PLA2R1 gene and within the HLA loci have been identified, whereas epitope spreading of PLA2R may predict treatment response. More recently, thrombospondin type 1 domain-containing 7A (THSD7A) antibodies have been discovered in primary membranous nephropathy . PMID: 28904948
6. PLA2R may play a role in some adolescent and preteen idiopathic membranous nephropathy patients but may be less frequently associated with idiopathic membranous nephropathy during childhood PMID: 27921164
7. Anti-M-type phospholipase A2 receptor (anti-PLA2R) and anti-THSD7A (thrombospondin type-1 domain-containing 7A) were detected only in membranous neurophathy (MN) patient sera and not in controls. PMID: 27634909
8. The frameshift mutation detected in the current study would result in premature stops of amino acid synthesis in PLA2R1 and SRPK1 proteins and hence resembles a typical inactivating mutation. PMID: 28212809
9. Single-nucleotide polymorphism in PLA2R1 gene is associated with primary membranous nephropathy. PMID: 26673907
10. blocking the ERRalpha-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERRalpha and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression. PMID: 27041564
11. Assessment of PLA2R autoimmunity is essential for patient management. Combination of PLA2R-Ab and PLA2R-Ag increases diagnosis sensitivity. PLA2R-Ab titer is a biomarker of disease severity at initial assessment, and the kinetics of the antibody are significantly correlated to disease evolution. PMID: 28257452
12. analysis of Japanese patients reveals that anti-PLA2R antibodies are present in idiopathic membranous nephropathy but not in secondary membranous nephropathy PMID: 27355365
13. Retrospective study to compare the value of serum anti-PLA2R antibody and glomerular PLA2R deposition in reflecting disease activity and renal function in Chinese patients with membranous nephropathy; serum anti-PLA2R antibody is more closely correlated with disease activity and renal function than glomerular PLA2R deposition. PMID: 28614271
14. PLA2R1 is increased in the airway epithelium in asthma, and serves as a regulator of airway hyperresponsiveness, airway permeability, antigen sensitization, and airway inflammation. PMID: 27448109
15. circulating anti-PLA2R antibodies are specific for primary membranous nephropathy. PMID: 26830547
16. PLA2R gene polymorphism is Associated with Increased Intima-Media Thickness of the Carotid Artery. PMID: 27025682
17. Report both serum and kidney levels of PLA2R1 autoantibody in idiopathic membranous nephropathy. PMID: 26369693
18. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. PMID: 26854647
19. genetic polymorphism is associated with systemic lupus erythematosus and lupus nephritis in a Chinese patients PMID: 26645973
20. Accordingly, PLA2R ABs assay seems to be promising tool not only to diagnose MN but also to predict the course of the disease and could open the way to personalize therapy. [review] PMID: 26576418
21. PLA2R1 expression in breast cancer cells is controlled by DNA methylation and histone modifications PMID: 26672991
22. Assessments of both serum PLA2R antibodies and PLA2R antigen in glomeruli were more sensitive for the diagnosis of PLA2R-related membranous nephropathy PMID: 25492250
23. Data indicate that enhanced granular expression of phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) was detected in 9.1% and 52.7%, respectively, of the patients with idiopathic membranous nephropathy (MN). PMID: 26393352
24. Anti-PLA2R antibodies were found in Japanese patients with idiopathic membranous nephropathy; however, the prevalence was lower than that of any other Asian country. PMID: 25412738
25. Suggest that PLA2R has a contributory role in the pathogenesis of paediatric idiopathic membranous nephropathy. PMID: 26194981
26. Renal biopsy PLA2R positivity was common in idiopathic membranous nephropathy (MN) and HBV-MN but rare in lupus-associated MN, and it was closely associated with serum PLA2R-Ab production. PMID: 26087695
27. Case Report: PLA2R positive membranous nephropathy in kidney transplant recipient with both IgA nephropathy and HCV infection long after kidney transplant from identical twin. PMID: 26031599
28. The detection and measurement of PLA2R-AB in idiopathic membranous nephropathy patients may be important tool in monitoring of the disease and efficacy of the treatment. PMID: 25953939
29. serological anti-PLA2R testing has diagnostic value for differentiating iMN from sMN, but it must be interpreted in context with patient clinical characteristics (degree of proteinuria, immunosuppressive treatment, time of detection). PMID: 25740009
30. Demonstrate pretransplantation circulating anti-PLA2R antibodies in a cohort of renal transplant recipients who prospectively developed recurrent disease. PMID: 25675198
31. The sPLA2 IB-PLA2R interaction stimulated podocyte apoptosis through activating ERK1/2 and cPLA2alpha and through increasing the podocyte AA content PMID: 25335547
32. Studies indicate that phospholipase A2 receptor 1 (PLA2R1) may act as a clearance or signaling receptor for secreted phospholipase A2 (sPLA2s). PMID: 25230085
33. An important role of PLA2R1 in controlling cancer cell death by influencing mitochondrial biology. PMID: 23994771
34. Data show there was strong epistasis between HLA-DQA1 single nucleotide polymorphism rs2187668 and the phospholipase A2 receptor 1 (PLA2R1) variant rs35771982. PMID: 25187357
35. Study showed that CTLD1-2 as well as the FNII domain of PLA2R were responsible for binding to collagen I and collagen-dependent migration in both mouse and human PLA2R. PMID: 25724334
36. Data show loss of VHL, stabilization of HIF-2alpha and increased c-MYC activity, binding and transcriptional repression, through induction of PLA2R1 DNA methylation closed to PLA2R1 transcriptional start site, results in decreased PLA2R1 transcription. PMID: 24657971
37. 15 of 154 patients with idiopathic membranous nephropathy had circulating autoantibodies to THSD7A but not to PLA2R1, a finding that suggests a distinct subgroup of patients with this condition. PMID: 25394321
38. This review compiles recent data demonstrating an unexpected tumor suppressive role of PLA2R1 and outlines the future work needed to improve our knowledge of the functions of this gene in cancer.[review] PMID: 24667060
39. Suggest HLA-DQA1 and PLA2R1 polymorphisms can predict idiopathic membranous nephropathy response to immunosuppressors and disease progression. PMID: 24262501
40. PLA2R1 plays a role in cancer as a tumor gene suppressor and is the major target antigen of auto-immune antibodies involved in idiopathic membranous nephropathy, a severe human kidney disease.[review] PMID: 24939538
41. We conclude that a decrease in PLA2R antibody level is associated with a decrease of proteinuria in patients with primary membranous nephropathy. PMID: 24610926
42. PLA2R staining sensitivity is much lower in the pediatric than the adult primary membranous glomerulopathy population, suggesting a more diverse and currently incompletely described set of etiologies for this disease in this group. PMID: 23903693
43. anti-PLA2R in serum of patients with idiopathic membranous nephropathy was confirmed as a reliable diagnostic marker. PMID: 24779214
44. The CC genotype and C allele at rs35771982 in PLA2R gene are associated with susceptibility to IMN in Chinese Hans. PMID: 24327152
45. We present the largest case series to date examining PLA2R1 involvement in membranous glomerulopathy PMID: 23196797
46. High levels of PLA2R antibodies are linked with active disease and a higher risk of declining renal function during follow-up in idiopathic membranous nephropathy. PMID: 23364522
47. the interaction between PLA2R1 and HLA-DQA1 risk alleles associates with the development of idiopathic membranous nephropathy in the Chinese population. PMID: 23813219
48. rare variants in the coding sequence of PLA2R1, including splice sites, are unlikely to explain the pathogenesis of idiopathic membranous nephropathy. PMID: 23431073
49. Data show that the genotyping technique of single nucleotide polymorphisms (SNPs) rs2187668 and rs4664308 within HLA-DQA1 and PLA2R1 is valuable for assessing susceptibility to idiopathic membranous nephropathy (IMN). PMID: 23194743
50. Increased staining for PLA2R in glomeruli of renal biopsies tightly correlates with the presence of PLA2R autoantibodies in the serum and this may help discriminate between primary and secondary membranous nephropathy. PMID: 22673885
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein.; [Soluble secretory phospholipase A2 receptor]: Secreted.; [Isoform 2]: Secreted.
組織特異性：

Expressed in podocytes (at protein level). Present in lung macrophage (at protein level). Highly expressed in kidney. Also expressed in pancreas, amnion, choriodecidua and placenta. Isoform 2 is expressed at much lower level.
數(shù)據(jù)庫鏈接：

HGNC: 9042

OMIM: 604939

KEGG: hsa:22925

STRING: 9606.ENSP00000283243

UniGene: Hs.410477

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human